Posts Tagged: Oncology

NGS is helping oncologists make informed treatment decisions

For decades, tissue-conserving surgery coupled with chemotherapy (either preceding or following surgery, depending on the size of the tumor(s)) followed by radiation has been the standard of care for the majority of cancers. Over the past fifteen years, chemoradiotherapy (concurrently dosing a patient with chemotherapy and radiation) has improved the overall survival rates especially for… Read article →


AMP Europe 2018

Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.  


Liquid biopsy to detect tumor DNA: The possibilities

An article published on WBUR’s CommonHealth blog opens a window into liquid biopsy, also referred to as blood biopsy, in its current and future state. The article discusses how this rapidly-evolving technology has the potential to transform the way we detect and treat cancer. The technology of liquid biopsy is rapidly evolving, but still has… Read article →



Webinar: A clinical view on PITX2 DNA methylation in high-risk breast cancer

A webinar program for oncologists and pathologists Thursday, Feb. 22, 2018 at 1:00 p.m. CET Anthracycline-based chemotherapy is the recommended standard-of-care for certain high-risk breast cancer patients including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. However, not all patients benefit equally from this chemotherapy. Learn more about a novel, validated marker that… Read article →


Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →


Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →


QIAGEN at ESMO 2016

Meet us there to discuss how our next-generation oncology solutions can take you from sample to insight! The ESMO_2016_Meeting is just around the corner, and we’re excited to see you there from Oct. 7 – 11 in Copenhagen! Here at QIAGEN, we are proud to be part of the collaborative effort to improve cancer care…. Read article →


QIAGEN’s companion diagnostic business highlighted in the Journal of Precision Medicine

A recent publication in the Journal of Precision Medicine highlights QIAGEN’s companion diagnostic business development and Modaplex platform. The July 2016 issue of the Journal_of_Precision_Medicine (JPM) features an article by Jessica Johnson called “Companion Diagnostics – a Burgeoning Market” (1). In this article, Johnson provides a brief account of the recent history of companion diagnostics… Read article →


ESMO guidelines committee update clinical recommendations for metastatic colorectal cancer

The European Society for Medical Oncology (ESMO ) is a leading European professional organization for medical oncology and is considered the reference society for oncology education and information. Comprised of more than 13,000 oncology professionals from over 130 countries, ESMO is a home for all oncology stakeholders, and connects professionals with diverse expertise and experience…. Read article →


New study suggests RT-PCR-based ALK assay useful in clinical practice

Anaplastic lymphoma kinase (ALK) gene rearrangements are found in 3–5% of lung adenocarcinomas (ADC) (2–4, Figure 1), and over 20 ALK fusion partners have been implicated in non-small-cell lung cancer (NSCLC) (5). Thanks to the relatively recent development of small molecule targeted therapies, the ALK oncogene is now targetable using ALK tyrosine kinase inhibitors (TKIs)… Read article →


QIAGEN partners to develop predictive tests in oncology

Yesterday, we announced that QIAGEN was entering into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients. See the full press release… Read article →